Skip to main content

Table 1 Patient characteristics according to VAT, SAT, and IMAT areas

From: Adipose tissue area as a predictor for the efficacy of apatinib in platinum-resistant ovarian cancer: an exploratory imaging biomarker analysis of the AEROC trial

Characteristic

All (N = 31)

VAT

P value

SAT

P value

IMAT

P value

Low (N = 12)

High (N = 19)

Low (N = 12)

High (N = 19)

Low (N = 5)

High (N = 26)

Age, N (%)

   

0.842

  

0.842

  

0.133*

 < 60 years

20 (64.5)

8 (66.7)

12 (63.2)

 

8 (66.7)

12 (63.2)

 

5 (100)

15 (57.7)

 

 ≥ 60 years

11 (35.5)

4 (33.3)

7 (36.8)

 

4 (33.3)

7 (36.8)

 

0 (0)

11 (42.3)

 

Histology at diagnosis, N (%)

   

0.917*

  

0.917*

  

1.000*

 High-grade serous carcinoma

24 (77.4)

9 (75.0)

15 (78.9)

 

9 (75.0)

15 (78.9)

 

5 (100)

19 (73.1)

 

 Low-grade serous carcinoma

1 (3.2)

0 (0)

1 (5.3)

 

0 (0)

1 (5.3)

 

0 (0)

1 (3.8)

 

 Endometrioid

2 (6.5)

1 (8.3)

1 (5.3)

 

1 (8.3)

1 (5.3)

 

0 (0)

2 (7.7)

 

 Clear cell

3 (9.7)

1 (8.3)

2 (10.5)

 

1 (8.3)

2 (10.5)

 

0 (0)

3 (11.5)

 

 Mucinous

1 (3.2)

1 (8.3)

0 (0)

 

1 (8.3)

0 (0)

 

0 (0)

1 (3.8)

 

ECOG performance status, N (%)

  

0.644*

  

0.644*

  

0.656*

 0

8 (25.8)

2 (16.7)

6 (31.6)

 

2 (16.7)

6 (31.6)

 

2 (40)

6 (23.1)

 

 1

22 (71.0)

10 (83.3)

12 (63.2)

 

10 (83.3)

12 (63.2)

 

3 (60)

19 (73.1)

 

 2

1 (3.2)

0 (0)

1 (5.3)

 

0 (0)

1 (5.3)

 

0 (0)

1 (3.8)

 

Number of previous chemotherapy lines, N (%)

  

0.763

  

1.000

  

0.800*

 1–2 lines

7 (22.6)

3 (25)

4 (21.1)

 

3 (25)

4 (21.1)

 

1 (20)

6 (23.1)

 

 3–6 lines

19 (61.3)

8 (66.7)

11 (57.9)

 

7 (58.3)

12 (63.2)

 

4 (80)

15 (57.7)

 

 > 6 lines

5 (16.1)

1 (8.3)

4 (21.1)

 

2 (16.7)

3 (15.8)

 

0 (0)

5 (19.2)

 

Interval between last chemotherapy and disease progression, N (%)

0.676

  

0.676

  

0.562*

 < 3 months

24 (77.4)

10 (83.3)

14 (73.7)

 

10 (83.3)

14 (73.7)

 

5 (100)

19 (73.1)

 

 ≥ 3 months and < 6 months

7 (22.6)

2 (16.7)

5 (26.3)

 

2 (16.7)

5 (26.3)

 

0 (0)

7 (26.9)

 

Dosage of apatinib, mean ± SD, g

69.86 ± 41.38

55.47 ± 24.84

78.95 ± 47.46

0.049

56.41 ± 24.02

78.36 ± 48.00

0.034

42.35 ± 16.23

75.15 ± 42.81

0.096

  1. Abbreviations: N number, VAT visceral adipose tissue, SAT subcutaneous adipose tissue, IMAT intermuscular adipose tissue, FIGO International Federation of Gynecology and Obstetrics, ECOG Eastern Cooperative Oncology Group, SD standard deviation, g gram
  2. *Fisher’s exact tests
Back to article page